# Research Study Comparing a New Medicine Fast-acting Insulin Aspart to Another Already Available Medicine NovoRapid/NovoLog in People With Type 2 Diabetes

Study · id `cardio:ct-nct03268005` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03268005](<https://clinicaltrials.gov/study/NCT03268005>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03268005

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1264 participants.

## Technical summary

Registry record NCT03268005. Randomized; quadruple masking; primary purpose treatment. Start 2017-09-19 (actual); primary completion 2019-01-07 (actual). Results posted on 2020-03-12.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1264 participants (enrolled count; ClinicalTrials.gov record NCT03268005, source copy `cardio:ctgov-nct03268005-2022-01-11`, retrieved 2026-10-26)
- Started: 2017-09-19 (actual) (ClinicalTrials.gov record NCT03268005, source copy `cardio:ctgov-nct03268005-2022-01-11`, retrieved 2026-10-26)
- Primary completion: 2019-01-07 (actual) (ClinicalTrials.gov record NCT03268005, source copy `cardio:ctgov-nct03268005-2022-01-11`, retrieved 2026-10-26)
- Completion: 2019-01-29 (actual) (ClinicalTrials.gov record NCT03268005, source copy `cardio:ctgov-nct03268005-2022-01-11`, retrieved 2026-10-26)
- Results first posted: 2020-03-12 (ClinicalTrials.gov record NCT03268005, source copy `cardio:ctgov-nct03268005-2022-01-11`, retrieved 2026-10-26)
- Countries: United States; Argentina; Bulgaria; Canada; Croatia; Czechia; Germany; Greece; Italy; Poland; Puerto Rico; Romania; Russia; Serbia; Slovakia; South Korea; Spain; Ukraine (ClinicalTrials.gov record NCT03268005, source copy `cardio:ctgov-nct03268005-2022-01-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03268005-2022-01-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
- Acronym: onset 9
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Faster-acting insulin aspart
- Intervention (Drug): Insulin aspart
- Intervention (Drug): Insulin degludec
- Intervention (Drug): Metformin
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9) (`cardio:pubmed-32209647`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 151a0b04e1994f263d3604e06b9670c117cb40034bd64d72b62500c341a7cd93
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
